Vaccines

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

A biotech startup's nomination for a top award validates its unique platform, which uses a patient's own cells to fight cancer and prepare for future pandemics.

Stand Up To Cancer funds a bold new strategy against pancreatic cancer, pairing an mRNA vaccine with cellular therapy to finally target the elusive KRAS gene.

European approval for Bavarian Nordic's pediatric mpox vaccine is a critical health breakthrough and a masterclass in strategic market positioning.

Medgene's new vaccine offers a first line of defense against a deadly, tick-borne parasite ravaging US cattle, highlighting a new era in rapid-response animal health tech.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

A breakthrough oral vaccine from Singaporean scientists promises to end a devastating fish virus, bolstering food security and transforming aquaculture economics.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

Despite passing all resolutions, Novavax faces a reckoning as nearly half of shareholders reject its pay plan, amplifying activist investor Shah Capital's demands.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.